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Abstract
Viral infection triggers an early host response through activation of pattern recognition receptors, including Toll-like
receptors (TLR). TLR signaling cascades induce production of type I interferons and proinflammatory cytokines involved in
establishing an anti-viral state as well as in orchestrating ensuing adaptive immunity. To allow infection, replication, and
persistence, (herpes)viruses employ ingenious strategies to evade host immunity. The human gamma-herpesvirus Epstein-
Barr virus (EBV) is a large, enveloped DNA virus persistently carried by more than 90% of adults worldwide. It is the causative
agent of infectious mononucleosis and is associated with several malignant tumors. EBV activates TLRs, including TLR2,
TLR3, and TLR9. Interestingly, both the expression of and signaling by TLRs is attenuated during productive EBV infection.
Ubiquitination plays an important role in regulating TLR signaling and is controlled by ubiquitin ligases and deubiquitinases
(DUBs). The EBV genome encodes three proteins reported to exert in vitro deubiquitinase activity. Using active site-directed
probes, we show that one of these putative DUBs, the conserved herpesvirus large tegument protein BPLF1, acts as a
functional DUB in EBV-producing B cells. The BPLF1 enzyme is expressed during the late phase of lytic EBV infection and is
incorporated into viral particles. The N-terminal part of the large BPLF1 protein contains the catalytic site for DUB activity
and suppresses TLR-mediated activation of NF-kB at, or downstream of, the TRAF6 signaling intermediate. A catalytically
inactive mutant of this EBV protein did not reduce NF-kB activation, indicating that DUB activity is essential for attenuating
TLR signal transduction. Our combined results show that EBV employs deubiquitination of signaling intermediates in the
TLR cascade as a mechanism to counteract innate anti-viral immunity of infected hosts.
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Introduction
Herpesviruses are large enveloped DNA viruses that establish
widespread persistent infections. The long coevolution has led to a
delicate balance between virus and host. For instance, the human
gamma-herpesvirus Epstein-Barr virus (EBV) is carried by over
90% of the adult world population, mostly without overt symptoms
[1], even though the virus is also causally involved in infectious
mononucleosis and a number of malignancies of lymphoid and
epithelial origin [2]. Upon primary infection, EBV establishes a
lifelong latent infection in memory B cells, characterized by expres-
sion of a limited set of viral gene products. For transmission, viral
particles are generated during the productive phase of EBV infection,
during which the full repertoire of viral lytic genes is expressed.
To successfully establish infection and replicate, herpesviruses
including EBV must withstand elimination by host defense
mechanisms. A first line of host defense is posed by the innate
immune system. Innate responses are initiated upon recognition of
conserved pathogen-associated molecular patterns (PAMPs) by
host pattern-recognition receptors (PRRs). Resulting signaling
cascades culminate in the production of type I interferons and pro-
inflammatory cytokines, whose actions limit viral replication by
direct anti-viral effects and through tailoring ensuing adaptive
immunity [3]. Among the PRRs contributing to anti-viral im-
munity are membrane-bound Toll-like receptors (TLRs) and
cytosolic RIG-I-like receptors (RLRs).
The importance of TLRs for controlling herpesvirus infection in
vivo is exemplified by an increased susceptibility to MCMV [4–6]
or HSV [7,8] in TLR2, TLR3, TLR7, and/or TLR9 knockout
mice as well as in mice lacking the TLR-signaling adaptor MyD88.
In humans, genetic studies found an increased incidence of
herpesvirus encephalitis in individuals with a defect in the TLR3
pathway, whereas susceptibility to pathogens outside the herpes-
virus family was not altered [9–13].
TLRs sense PAMPs from a wide variety of pathogens and
a number of herpesvirus-derived TLR ligands has now been
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identified [14]. For EBV, they include virion components that
trigger cell-surface displayed TLR2 [15,16] and virus-derived
nucleic acids, such as dsRNA intermediates and genomic DNA,
that are sensed by intracellular TLR3, TLR7, and TLR9 [17–20].
Upon ligand binding, dimerized TLRs interact with Toll-IL-1
receptor (TIR)-domain containing adaptors [21,22]. All TLRs
except TLR3 recruit adaptor protein MyD88, which leads to
phosphorylation of IL-1 receptor-associated kinase (IRAK)-1 and
subsequent activation of tumor necrosis factor-associated factor
(TRAF)6. To regulate signal transduction and recruit kinase
complexes, TRAF6 catalyzes the formation of lysine(K)63-linked
polyubiquitin chains on itself and on NF-kB essential modulator
(NEMO, or IkB kinase (IKK)c). Activation of the IKK complex
(comprising IKKa, IKKb, NEMO) then leads to phosphorylation
and ubiquitination of the inhibitor of NF-kB, IkBa. This K48-
linked ubiquitination targets IkBa for proteasomal degradation,
thereby allowing NF-kB to translocate into the nucleus and initiate
transcription of genes encoding proinflammatory cytokines. TLR
signaling can also lead to the production of type I interferons
(IFN). Stimulation of TLR7 and TLR9, expressed by plasmacytoid
dendritic cells (pDC) for instance, leads to production of type I
IFNs through activation of transcription factor IRF7 (signaled
through IRAK1/TRAF6/IKKa). TLR3 or TLR4 ligation results
in type I IFNs production following signaling through the adaptor
molecule TIR domain-containing adapter inducing IFNb (TRIF).
In addition to this, TRIF-mediated signaling can induce (delayed)
activation of NF-kB by triggering TRAF6. These pathways offer
several possibilities for interference by (herpes)viruses. Indeed, we
have previously reported that mRNA expression levels of several
TLRs were reduced in latently and productively EBV-infected B
cells [23].
Through post-translational ubiquitin modification, TLR signal-
ing pathways are tightly regulated by cellular ubiquitin ligases and
deubiquitinases (DUBs) [24]. The cellular DUBs A20 [25] and
CYLD [26] for instance, downmodulate TLR signaling through
deubiquitination of TRAF6. Several viruses interfere with the
expression of cellular DUBs or encode DUBs themselves [27,28].
Using probes that identify DUBs by interacting with their catalytic
sites, conserved DUB activity was found in the large tegument
protein of several herpesviruses [29–31]. The EBV homolog of this
large tegument protein, BPLF1, consists of 3149 amino acids and
its DUB activity is contained in the first N-terminal 204 residues
[31]. In the absence of the cloned full-length BPLF1 gene, or
BPLF1-specific monoclonal antibodies allowing immunoprecipi-
tation of virally expressed protein, in vitro studies so far have used
epitope-tagged BPLF1 fragments encoding up to the first 325 most
N-terminal amino acids. Besides BPLF1, a bioinformatics screen
identified two other EBV proteins with putative DUB activity,
BSLF1 and BXLF1 [32].
Since EBV can activate TLR2, TLR3, TLR7, and TLR9, it
would be of benefit if EBV were to evade innate immune
activation. Here, we examined whether EBV DUB activity was
present during productive infection in B cells and whether it could
inhibit innate immune signaling.
Materials and Methods
Cells
AKBM cells are derived from an EBV+ Burkitt’s lymphoma
(BL) cell line (EBV strain Akata) by stable transfection with the
plasmid pHEBO-prBMRF1-ratCD2-GFP yielding inducible rat
CD2-GFP expression in productively EBV-infected cells (see
below) [33]. AK31 cells are derived from an EBV-negative
subclone of the parental Akata BL cell line by stable transfection to
achieve constitutive expression of the ratCD2-GFP fusion protein
in part of the population. Jijoye cells are EBV+ B cells that express
LMP1 [34]. AKBM, AK31, and Jijoye cells were maintained in
RPMI 1640 medium (Invitrogen) supplemented with 10% FBS
(Sigma), 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL
streptomycin, and 0.3 mg/mL hygromycin B (AKBM cells) or
1 mg/mL geneticin (AK31 cells).
Human embryonic kidney 293T cells were maintained in
Dulbecco’s modified Eagle medium (DMEM; Invitrogen) supple-
mented with 10% FBS (Sigma) and 2 mM L-glutamine (Invitro-
gen). 293 cells expressing human TLR2 and CD14 (293-TLR2/
CD14) or CD14 alone (293-CD14) were described previously [35]
and 293 cells expressing human TLR3 (293-TLR3) were obtained
from InvivoGen (San Diego, CA).
Productive EBV infection and EBV particles
Productive EBV infection was induced in AKBM cells as
described [33]. Briefly, B cell surface IgG was cross-linked by
incubation with 50 mg/mL goat F(ab9)2 fragments to human IgG
(Cappel; MP Biomedicals) for the times indicated. Percentages of
productively infected cells were determined based on induced
expression of the rat CD2-GFP reporter protein. To discriminate
(immediate) early and late stages of productive infection, viral
DNA replication and late phase gene expression were inhibited by
treatment with 300 mg/mL phosphonoacetic acid (PAA, pH 7.4 in
100 mM HEPES, Sigma Aldrich) starting 1 hour prior to anti-IgG
treatment. To exclude secondary effects of antibody (Ab)
treatment or the presence of PAA, control EBV2 AK31 cells
were included in parallel.
Directly pelleted EBV (strain B95.8) was purchased from
Advanced Biotechnologies Inc. (batch #106-176) and lysates of
561010 particles/mL were prepared in reducing sample buffer
(200 mM Tris-HCl [pH 6.8], 3% SDS, 10% glycerol, 1 mM
EDTA, 50 mM DTT, 0.05% bromophenol blue).
Plasmids
BPLF1 (aa 1–325), BSLF1, or BXLF1 in frame with an N-
terminal HA- (YPYDVPDYA) or Flag- (DYKDDDDK) tag were
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Epstein-Barr virus (EBV) is a human herpesvirus that
persistently infects .90% of adults worldwide. One factor
underlying the ability of EBV to establish such widespread
and lifelong infections is its capacity to escape elimination
by the human immune system. Among the first lines of
defense against viral infection is the human Toll-like
receptor (TLR) system. These receptors can detect the
presence of viruses and initiate an intracellular protein
signaling cascade that leads to the expression of immune
response genes. The activation status of many proteins in
this signaling cascade is regulated by the addition of
ubiquitin tags. EBV has previously been reported to
encode enzymes, called deubiquitinases (DUBs), which
are capable of removing such ubiquitin tags from
substrate proteins. In our study, we found that one of
these enzymes, BPLF1, functions as an active DUB during
EBV production in infected cells before being packaged
into newly produced viral particles. Furthermore, our study
provides insight into the way in which EBV can subvert the
human immune response, as we show that BPLF1 can
remove ubiquitin tags from proteins in the TLR signaling
cascade. This inhibits TLR signaling and decreases the
expression of immune response genes.
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PCR amplified from EBV B95.8 genomic DNA using the primers
listed in Table 1. An additional Flag-tagged BPLF1 (aa 1–325)
construct was generated by PCR amplification based on EBV
strain Akata. Fragments were cloned into Gateway donor vectors
and subcloned into the mammalian expression vector pMaxClon-
ing (Lonza). Full-length BPLF1 (FL BPLF1) with an N-terminal
Flag-tag and C-terminal HA-tag was engineered in pMaxCloning
by joining three overlapping fragments of B95.8 BPLF1 amplified
from genomic DNA (see Table 1), using unique restriction sites
present inside the BPLF1 open reading frame (EcoRI and ClaI).
The resulting sequence was identical to the B95.8 BPLF1 open
reading frame except for a deletion spanning nucleotides 1102–
1131 (two out of eight PASAA repeats) and a T to A mutation at
nucleotide position 1192. BPLF1 (aa 1–325) mutants C61A (TGC
to GCC), D86/90R (two times GAC to CGC), or D86/90G (two
times GAC to GGC) were generated by site-directed mutagenesis
using Pfu Turbo polymerase (Agilent Technologies) and the
primers listed in Table 1. Correctness of all constructs was verified
by sequencing.
Other plasmids used were: pcDNA3-Flag-MyD88 (M. Muzio,
Milan, Italy), IRAK1, Flag-TRAF6 (Tularik), pcDNA3-Flag-
IKKa (A. Baldwin, Chapel Hill, USA), IkBa, His-NEMO (IKKc),
Flag-A20, pcDNA3.1-HA-ubiquitin (T. Chiba, University of
Tsukuba, Japan), and pUNO-hTLR2 (InvivoGen).
Transfections
To transiently express individual EBV proteins, 293T cells
(1.56106) were transfected in suspension with a total of 4 mg vector
DNA using Lipofectamine 2000 according to manufacturer’s
instructions (Invitrogen) and seeded in 6-well plates. 16 hours post-
transfection, cells were lysed for DUB profiling or immunoblotting
(see below).
To visualize general protein ubiquitination, 293T cells (1.56106)
were transfected with a combination of plasmids encoding HA-Ub
(1 mg) and BPLF1 variants (2 mg), supplemented with empty
vector (1 mg). Cells were seeded in 6-well plates and lysed
40 hours post-transfection in reducing sample buffer (200 mM
Tris-HCl [pH 6.8], 3% SDS, 10% glycerol, 1 mM EDTA,
50 mM DTT, 0.05% bromophenol blue).
To study IkBa degradation, 293T cells (16106) were transfected
in suspension using 3 mg DNA and 13 mL PEImax (Brunschwig
Chemie). After 40 hours, cells were stimulated with 10 ng/mL
MALP-2 and post-nuclear lysates were prepared.
DUB profiling
Active DUBs were labeled in cell lysates as previously described
[36]. In brief, post-nuclear cells were prepared in lysis buffer
(50 mM Tris-HCl, 250 mM sucrose, 5 mM MgCl2, 1 mM DTT,
0.5% CHAPS, and 0.1% NP40). DUB labeling was performed for
30 min at 37uC in lysis buffer containing 1 mg/mL protein
extract, 1 mM 5-carboxytetramethylrhodamine (TMR)-conjugated
ubiquitin-based probe, and two equivalents (v/v relative to probe)
50 mM NaOH to neutralize the pH. Reactions were terminated
by the addition of reducing sample buffer prior to heating at 90uC
for 10 min, after which proteins were resolved by SDS-PAGE (4%–
12% gradient gel) and visualized by in-gel fluorescence imaging.
Where indicated, gels were further used for immunoblotting.
Antibodies (Abs)
BPLF1-specific rat monoclonal Abs were prepared by immu-
nizing Lou/C rats with OVA-coupled peptides encompassing
BPLF1 amino acids 2–17 (peptide A: SNGDWGQSQRTRGTGP)
and amino acids 78–94 (peptide B: PLTSRPELDEVLDEGAR) of
B95.8.
To detect other EBV proteins, the following Abs were used:
mouse anti-BZLF1, mouse anti-BGLF5 (311H) [37], rabbit poly-
clonal anti-gp42 (PB1112), and mouse anti-LMP1 (clone CS1-4).
Other Abs included: mouse anti-Flag (M2, F3165, Sigma-Aldrich),
rat anti-HA (3F10, 11867423001, Roche Diagnostics), mouse anti-
His (5H1, HyTest Ltd), mouse anti-b-actin (Clone C4,
MAB1501R, Millipore), mouse anti-transferrin receptor (H68.4,
13–6800, Life Technologies), mouse anti-p97 (#612183, BD
Transduction laboratories), and rabbit anti-histon H3 (Cell
Signaling Tech #9715). Specific Abs against signaling intermedi-
ates included rabbit anti-TRAF6 (H274, sc-7221, Santa Cruz, for
immunoprecipitation) and mouse anti-TRAF6 (sc-8409, Santa
Cruz, for immunoblotting), rabbit anti-NEMO (sc-8330, Santa
Cruz), rabbit anti-IkBa (sc-203, Santa Cruz), and rabbit anti-NF-
kB (sc-372, Santa Cruz).
For flow cytometry, goat anti-mouse allophycocyanin-conjugat-
ed (APC; M101, Leinco Technologies) or fluorescein isothiocya-
nate-conjugated (FITC; Dako) Abs were used as second step. For
immunoblotting, HRP-conjugated secondary Abs used were: anti-
rat Ig (light-chain specific, #112-035-175, Jackson), anti-mouse Ig
(light-chain specific, #115-035-174, Jackson), and anti-rabbit Ig
(4030-05, Southern Biotech). Secondary Abs used for immunoflu-
orescence were anti-Mouse Ig-Cy3 (715-165-151, Jackson), anti-
Rabbit Ig-Dylight 488 (711-485-152, Jackson), and anti-Rat
Ig-Dylight 488 (712-485-153, Jackson).
Flow cytometry
For intracellular staining, cells were fixed with PBS/1%
formaldehyde and permeabilized using 0.5% saponin (Sigma-
Aldrich). Samples were measured on a FACSCantoII or
FACSCalibur flow cytometer (BD Biosciences) and analyzed
using FACSDiva (BD Biosciences) and FlowJo software (Tree
Star).
Immunoblotting
Immunoblot analysis was performed as described [33]. In brief,
post-nuclear cell lysates were prepared as follows: cells were lysed
using NP40 lysis buffer (0.5% Igepal-CA630, 50 mM Tris HCl
[pH 7.5], 150 mM NaCl, 10 mM Leupeptin, and 1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride), post-nuclear lysates were
clarified by centrifugation, and proteins in the lysates were
denatured with reducing sample buffer. Where indicated, nuclear
fractions were prepared by resuspending the nuclear pellet
obtained after centrifugation in NP40 lysis buffer through
sonification. Solubilized proteins were resolved by SDS-PAGE
and transferred to polyvinylidene difluoride (PVDF) membranes
(Bio-Rad). Membranes were incubated with specific primary Abs
followed by HRP-conjugated secondary Abs and reactive protein
bands were visualized using ECL Plus detection kit (GE Health-
care) and ImageQuant LAS 4000 imager (GE Healthcare Life
Sciences). Densitometric quantification of staining intensity was
performed using Quantity One software (Bio-Rad).
Luciferase reporter assays and IL-8 ELISA
Transfections were conducted in suspension using Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s protocol
in 96-well flat-bottom plates. Briefly, 293(T) cells (56104) were
transfected with a total of 200 ng DNA containing 75 ng pGL3-
firefly luciferase controlled by either five NF-kB binding sites (NF-
kB-luc), part of the human E-selectin promoter (pELAM-luc), or
the human IFN-b promoter together with 4 ng of HSV thymidine
kinase driven Renilla luciferase for normalization (pGL3-TK
vector), and indicated amounts of plasmids encoding EBV genes
or controls. Where indicated, 293T cells were cotransfected with
EBV Deubiquitinase Inhibits TLR Signaling
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5 ng pUNO-TLR2. TLR signaling was induced either by
cotransfecting activator proteins MyD88 (15 ng), IRAK1 (8 ng),
TRAF6 (40 ng), or IKKa (75 ng) or by treatment for 7 hours with
10 ng/mL TLR2 agonist MALP-2 (sc-221869, Santa Cruz),
10 mg/mL TLR3 agonist poly(I:C) (HMW, InvivoGen), or
6.56106 EBV particles/mL (purified virus, batch 4H0012-PV,
Advanced Biotechnologies Inc) starting at 16 hours post-transfec-
tion. Cells were lysed in Passive Lysis Buffer and Firefly and Renilla
luciferase activities were measured using the Dual-Luciferase
Reporter Assay System according to manufacturer’s instructions
(Promega). Data were normalized for Renilla luciferase activity and
presented as percentage firefly luciferase activity relative to the
stimulated transfected control sample, mean 6 S.D.
To study effects on cellular IL-8 production, 293-TLR2/CD14
cells were transfected in 96-well flat-bottom plates with 200 ng
EBV or control plasmids and were stimulated with 10 ng/mL
MALP-2 or 6.56106 EBV particles/mL (batch 4H0012-PV) at
24 hours post-transfection in 100 mL DMEM (transfection effi-
ciencies around 60%). Following 8 hours of stimulation, levels of
IL-8 secreted in the culture supernatants were measured by ELISA
using PeliKine Compact human IL-8 ELISA kit (Sanquin
Reagents) according to manufacturer’s instructions.
Cellular deubiquitination assay
293T cells were transfected with HA-ubiquitin together with
either Flag-TRAF6 or His-NEMO and empty vector, Flag-BPLF1,
Flag-BPLF1C61A, or Flag-A20. Post-nuclear extracts of transfected
cells were prepared in lysis buffer (50 mM Tris-HCl [pH 7.5],
150 mM NaCl, 0.5% Igepal [w/v], 1 mM dihiothreitol [DTT],
1 mM phenylmethylsulfonyl fluoride (PMSF), 25 mg/mL Leu-
peptin, 25 mg/mL aprotinin, 1 mM benzamidine, 10 mg/mL
trypsin inhibitor), in case of TRAF6 supplemented with 50 mM
NaF and 1 mM Na3VO4. Samples containing TRAF6 were
denatured by addition of SDS to a final concentration of 1%
and heating at 95uC for 5 minutes, after which SDS was diluted
by adding additional lysis buffer. TRAF6 was precipitated by
incubating with anti-TRAF6 Ab overnight at 4uC with constant
agitation and for an additional 5 hours with protein A-sepharose
beads. His-NEMO was precipitated by incubation with nickel-
NTA agarose beads (Qiagen) overnight at 4uC. After washing,
precipitated proteins were eluted in reducing sample buffer and
analyzed by immunoblotting.
In vitro deubiquitination of signaling intermediates
293T cells were cotransfected with HA-ubiquitin and either
Flag-TRAF6, His-NEMO, or IkBa. 24 hours post transfection,
IkBa-transfected cells were additionally treated with 50 mM
MG132 and 10 ng/mL TNFa for 2 hours. Post-nuclear cells
lysates were prepared using NP40 lysis buffer with protease
inhibitor cocktail (Roche) and 20 mM NEM. To precipitate
(ubiquitinated) TRAF6, NEMO, or IkBa, cell lysates were incu-
bated overnight at 4uC with constant agitation with anti-Flag M2
Abs and protein G sepharose beads, nickel NTA beads (Qiagen),
or anti-IkBa Abs and protein A sepharose beads, respectively.
Flag-TRAF6(-Ubn) was released from the beads using 1 mg/mL
Flag peptide (Sigma) and His-NEMO(-Ubn) was eluted using
250 mM imidazole. The thus obtained ubiquitinated signaling
proteins were incubated for 4 hrs at 37uC in DUB assay buffer
(50 mM HEPES-NaOH pH 8.0, 10% glycerol, 3 mM DTT) with
Flag-tagged BPLF1, BPLF1C61A, or A20 DUB proteins that were
purified from separately transfected 293T cells using anti-Flag Abs
and protein G sepharose beads. Samples were analyzed by
immunoblot analysis.
Immunofluorescence
293T cells (30.000) were transfected with plasmids encoding
BPLF1 and signaling intermediates (125 ng each) using Lipofecta-
mine 2000 and cultured overnight in Lab-Tek II chamber slide
system (Thermo Scientific). Cells were fixed using 3% parafor-
maldehyde in PBS for 30 minutes at 37uC and permeabilized by
Table 1. Primer sequences for cloning EBV putative DUBs.
Gene product Amino acids F/R* Primer sequence (59-39)
Flag-FL BPLF1-HA 2–815 F GGGGTACCCAATTGCCACCATGGATTACAAGGATGACGACGATAAGAGTAAC
GGCGACTGGGGGCAAAGC
R GTGGGGACCTGCAGATGTCCCG
671–1339 F GTCCGACTCTGAAGAAGCGGAGAGCG
R ATAGTTTAGCGGCCGCTTAGGATGAGCGTTTGGGAGAGCTGATTCTGC
1189–3149 F CGGGGCCGCAAAGAACCCCACG
R ATAGTTTAGCGGCCGCTTAAGCGTAATCTGGAACATCGTATGGGTACAGATACAAA
AACTTGAGTCTCTCGAGG
Flag-BSLF1 2–874 F GGGCTCGAGACCATGGATTACAAGGATGACGACGATAAGTCCGCCCCCGTCGTCATCAAGG
R GGGTCTAGACTAGTTCGGGAGAGTCTCTGAGAAG
Flag-BXLF1 2–607 F GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCTCGAGACCATGGATTACAAGGATGA
CGACGATAAGGCTGGATTTCCAGGAAAGGAGGCCGCTGGATTTCCAGGAAAGGAGGCC
R GGGGACCACTTTGTACAAGAAAGCTGGGTCTCTAGACTAGTCCCGATTTCCCCTCTC
Flag-BPLF1 2–325 F GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCTCGAGACCATGGATTACAAGGATGACGAC
GATAAGAGTAACGGCGACTGGGGGCAAAGC
R GGGGACCACTTTGTACAAGAAAGCTGGGTCTCTAGACTAAGGACTATACCTGGCGGCAGGG
HA-BPLF1 2–325 F GGGGTACCCAATTGCTCGAGCCACCATGTACCCATACGATGTTCCAGATTACGCTAGTAACG
GCGACTGGGGGCAAAGC
R GGGGACCACTTTGTACAAGAAAGCTGGGTCTCTAGACTAAGGACTATACCTGGCGGCAGGG
*F: forward, R: reverse.
doi:10.1371/journal.ppat.1003960.t001
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incubation with PBS/1% Triton X-100/0.1% sodium citrate for
5 minutes at room temperature. After blocking for 60 minutes
with PBS/5% BSA, samples were incubated with primary Abs in
PBS/1% BSA/0.1% Triton X-100 for 60 minutes, washed, and
incubated for 60 minutes with fluorescently labeled secondary Abs
together with DNA stain TO-PRO-3 (Life Technologies). Slides
were embedded in Mowiol (Brunschwig Chemie) and analyzed
using a confocal microscope (Leica SP5) and Leica Application
Suite Advance Fluorescence software.
Results
The large tegument protein BPLF1 acts as an active
deubiquitinase during productive EBV infection
To determine if EBV expresses active viral DUBs, we profiled
lytically and latently EBV-infected B cells. Productive infection
was induced in the latent EBV+ B cell line AKBM by treatment
with anti-human IgG antibodies (Abs) to crosslink the B cell
receptor and thereby reactivate EBV [33]. At 26 hours of induc-
tion, up to 52% of cells had entered the lytic cycle, as visualized by
rat CD2-GFP reporter expression (Fig. 1a). Post-nuclear cell
lysates were incubated with a fluorescently labeled ubiquitin (Ub)-
based, active-site directed probe (Ub-VME) [36]. This probe
interacts with the active site cysteines of DUBs to form a covalent
adduct. The fluorescently-labeled active DUB can then be
visualized following SDS-PAGE by in-gel imaging. Using this
approach, numerous Ub-VME-reactive species were visible in
latently infected AKBM cells, likely representing cellular DUBs
(Fig. 1b, lane 1). After 9 and 26 hours of anti-IgG treatment, an
additional high molecular weight band of .200 kDa appeared,
suggestive of induced expression of a DUB at late times of
productive EBV infection (arrow, lanes 4 and 5, and Fig. S1 for
enlarged view).
To investigate whether this DUB was virus-encoded, we
compared the DUB profiles of EBV+ B cells (AKBM) to those of
control EBV2 B cells (AK31). Both cell lines were either mock-
treated or treated with anti-IgG for 24 hours and active DUBs
were visualized in post-nuclear lysates (Fig. 1c, lanes 1–4). The
high molecular weight species reacting with the Ub-VME probe in
productively infected AKBM cells (Fig. 1c, lane 4) was not
observed in the EBV2 AK31 cells, even after treatment with anti-
IgG (Fig. 1c, lanes 2). This suggests that the active DUB appearing
in productively infected B cells is encoded by EBV.
Earlier, three EBV proteins were reported to display DUB
activity in vitro: BPLF1, BSLF1, and BXLF1 [31,32]. To examine
whether any of these corresponded to the active DUB observed in
productively infected B cells, the DUB profile of EBV-infected B
cells was compared to those of 293T cells that transiently
expressed the Flag-tagged BPLF1, BSLF1, or BXLF1 protein
(Fig. 1c). By intracellular FACS staining, the BXLF1 and BSLF1
proteins were detected in around 50% of cells (Fig. 1d). In
contrast, full-length BPLF1 (FL BPLF1) was detectable in only up
to 27% of cells, likely due to the large size of the protein (,3150
amino acids). So far, others have used N-terminal fragments of the
BPLF1 protein comprising the catalytic site for DUB activity in
their studies (varying in length from 205 to 325 aa) [38–41]. Thus,
we transfected 293T cells in parallel with a vector encoding the
N-terminal 325 amino acids of BPLF1, which yielded higher
transfection efficiencies (up to 53% positive cells, Fig. 1d) than full-
length BPLF1.
Ub-VME-labeled bands corresponding to the BXLF1 or BSLF1
proteins were not observed by DUB profiling of transfected 293T
cells (Fig. 1c, lanes 7 and 8), indicating that these display very
little or no DUB activity. Both EBV proteins contain nuclear
localization signals and (a proportion of) these proteins are present
in the nucleus. Although intracellular FACS staining (Fig. 1d)
demonstrated expression of Flag-BSLF1 as well as Flag-BXLF1
proteins in transfected cells, they could have been absent from the
post-nuclear cell lysates used for DUB profiling. However, Flag-
specific immunoblots of the gels used for fluorescence imaging
showed that both BSLF1 and BXLF1 were present in the post-
nuclear lysates (Fig. 1e, lanes 2 and 3). In our hands neither BSLF1
nor BXLF1 exerted in vitro cleavage of fluorogenic Ub-AMC
substrates or reduction in Ub-protein adducts in 293T cells
expressing HA-ubiquitin (data not shown). Furthermore, we did
not find specific Ub-VME-reactive proteins corresponding to the
sizes of these two proteins in productively EBV-infected AKBM
cells (Fig. 1c, lane 4). These combined results imply that BSLF1
and BXLF1 do not behave as active DUBs when expressed in
cells.
In contrast, transfection of full-length BPLF1 in 293T cells
resulted in expression of an active DUB visible as a specific Ub-
VME reactive band migrating over 200 kDa (Fig. 1c, lane 6). The
size of this band corresponded to that observed in lytically infected
AKBM cells (lane 4), suggesting that the large DUB expressed
during productive EBV infection is BPLF1. Upon cellular expres-
sion of full-length BPLF1, an additional smaller active DUB
fragment was visible around 42 kDa (asterisk, lane 6). Interesting-
ly, transfection of the N-terminal 325 aa of BPLF1 also yielded this
smaller fragment, in addition to the expected band at 46 kDa
(corresponding to 36 kDa of BPLF1 covalently linked to the Ub-
VME probe of 10 kDa, lane 9). The active fragment of ,42 kDa
(corresponding to ,280 aa) could have arisen upon alternative
expression or processing of BPLF1. Others have also reported the
presence of a smaller fragment upon expression of an N-terminal
part of BPLF1 [38,42]; here, we show for the first time that a
similar fragment is generated upon expression in 293T cells of full-
length BPLF1.
To enable the study of BPLF1 protein expression during natural
EBV infection (i.e. without (Flag-)epitope tag), we generated
monoclonal Abs against two peptides in the N-terminal domain of
this protein (based on the B95.8 EBV strain, see Fig. S2a). In
immunoblots of transfected 293T cells, mAb 1F2 (epitope: BPLF1
residues 78–94) reacted with N-terminal fragments of BPLF1 of
both the B95.8 and Akata EBV strains (Fig. S2b, Fig. 1f lane 9,
and Fig. S3b lane 1). Importantly, this BPLF1-specific Ab visua-
lized the full-length protein and shorter fragment in transfected
293T cells and also the active DUB expressed in productively
infected AKBM cells (Fig. 1f, lanes 6 and 4, respectively, and Fig.
S3), indicative of BPLF1 being expressed during the EBV lytic
cycle.
Thus, for two out of the three putative EBV DUBs, BSLF1 and
BXLF1, we did not find indications for DUB activity in cells. The
large tegument protein BPLF1, on the other hand, appeared to
interact with a functional probe both in transfected 293T cells and
in EBV-producing B cells, implying that it acts as an active DUB
during late times of productive EBV infection. Since both full-
length BPLF1 and the N-terminal part yielded the same active
smaller fragment, a construct expressing the N-terminal 325 aa of
BPLF1 was used in further assays.
BPLF1 interferes with TLR-mediated NF-kB activation
In view of the critical role of (de)ubiquitination in regulating
TLR signal transduction, we next addressed the question: does
EBV exploit virus-encoded DUBs to evade innate immune acti-
vation signaled through TLRs? To this end, we monitored NF-kB
activity in 293T cells transfected with an NF-kB-responsive firefly
luciferase reporter. Co-transfection of MyD88, the adaptor
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molecule used by all TLRs except TLR3, resulted in robust
activation of NF-kB (,50-fold induction of luciferase activity
compared to control cells; Fig. 2a). Upon additional introduction
of each of the three EBV proteins in these cells, expression of
BPLF1 resulted in a dose-dependent inhibition of NF-kB activation.
BXLF1 and BSLF1 did not substantially affect NF-kB activation
Figure 1. EBV BPLF1 is a DUB active during productive infection. EBV+ AKBM BL cells were treated with anti-human IgG (aIgG) to induce viral
replication. (a) At the indicated times post induction, percentages of productively EBV-infected AKBM cells were determined by flow cytometric
analysis of induced ratCD2-GFP reporter expression. (b) In post-nuclear AKBM cell lysates, active DUBs were labeled with a fluorescent Ub-VME probe,
resolved by SDS-PAGE, and visualized by in-gel fluorescence imaging. The arrow indicates a band appearing in AKBM cells after 9 hours of lytic cycle
induction (lanes 4 and 5). (c) DUB profiles of EBV2 AK31-rCD2-GFP cells (AK31, lanes 1 and 2), EBV+ AKBM cells (lanes 3 and 4), and transfected 293T
cells (lanes 5–9). In parallel with the EBV+ AKBM cells, EBV2 control AK31 cells were treated with aIgG for 24 hours; this resulted in productive
infection in 56% of AKBM cells; AK31 cells included a population of 45% that expressed ratCD2-GFP from a constitutive promoter irrespective of aIgG
treatment (data not shown). For comparison, 293T cells were transfected with constructs encoding three (putative) EBV DUBs: BPFL1, BXLF1, BSLF1, or
the 325 aa N-terminal part of BPLF1. The asterisk marks a smaller fragment observed upon transfection of 293T cells with full-length or the N-terminal
part of BPLF1 (lanes 6 and 9). Left and right panels are parts of one gel displayed at different exposures. (d) Sixteen hours post-transfection,
percentages of 293T cells expressing BPLF1, BXLF1, BSLF1 or the N-terminal fragment of BPLF1 were determined by intracellular FACS staining for the
Flag-tag. (e) Immunoblot of part of the gel in c probed with an anti-Flag Ab to detect transfected BXLF1 and BSLF1 (sequential staining following 1F2,
see in f). (f) Immunoblot of the gel in c probed with the BPLF1-specific mouse monoclonal Ab 1F2. Both panels are part of one gel presented at
different exposures.
doi:10.1371/journal.ppat.1003960.g001
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following MyD88 signaling (Fig. 2a), in line with their undetectable
DUB activity in cells. Immunoblots revealed comparable amounts
of MyD88 protein in each sample. The BPLF1 and BXLF1 proteins
were clearly detectable in the post-nuclear cell lysates. BSLF1
protein levels, however, appeared much lower (data not shown),
representing low expression and/or a predominantly nuclear locali-
zation of this EBV protein. Overexpression of the cellular DUB A20
in these cells, as a control known to inhibit TLR signaling, was also
difficult to detect by immunoblot (data not shown), yet strongly
counteracted NF-kB activation (Fig. 2a).
As a more physiological alternative to initiating TLR signaling
by transfection of MyD88, we stimulated 293 cells that stably
expressed TLR2 and CD14 (293-TLR2/CD14) or TLR3 (293-
TLR3) with their cognate ligands. TLR2-mediated NF-kB acti-
vation upon MALP-2 stimulation was inhibited by BPLF1 and
A20, but not by BXLF1 or BSLF1 (Fig. 2b). In contrast to the
MyD88-dependent TLR2, TLR3 activates NF-kB through a
different adaptor molecule, TRIF. This pathway, stimulated by
poly(I:C) treatment, was also repressed by EBV BPLF1 as well as
by the control DUB A20 (Fig. 2c, left panel). In addition, TLR3
stimulation induces type I IFN production. Activation of an IFN
b-reporter was also strongly reduced upon expression of BPLF1 –
and control A20 – in poly(I:C)-stimulated 293-TLR3 cells (Fig. 2c,
right panel).
Finally, we tested what the consequences would be of EBV
DUB expression for TLR activation of endogenous proinflamma-
tory cytokine production (Fig. 2d). Stimulation of 293-TLR2/
CD14 cells with MALP-2 ligand induced the production of IL-8
and this was counteracted by expression of BPLF1. As EBV has
also been reported to activate TLR2 [16], we performed the same
experiments using viral particles rather than MALP-2 to stimulate
TLR2 signaling. In response to EBV particles, both NF-kB
activation and IL-8 production occurred to levels comparable to
those observed for MALP-2 stimulation in 293-TLR2/CD14 cells
(Fig. 2b and d). No NF-kB activation or IL-8 production was
observed upon stimulation of TLR2-negative 293-CD14 cells (not
shown) indicating that the EBV-induced response was mediated by
TLR2. Moreover, BPLF1 reduced NF-kB-luciferase and IL-8
production also upon TLR stimulation by EBV; BXLF1 and
BSLF1 had no influence in this context (Fig. 2b and d). These
results indicate that EBV BPLF1 inhibits proinflammatory
cytokine production by cells in which the innate immune system
has been activated by viral particles.
Taken together, we found that one of the (putative) EBV DUBs,
the large tegument protein BPLF1, counteracts both MyD88- and
TRIF-dependent TLR signal transduction pathways.
The ability of BPLF1 to modulate TLR signaling correlates
with its deubiquitinase activity
To assess whether BPLF1 relies on deubiquitination to interfere
with TLR signaling, we used three previously reported BPLF1
mutants (C61A, D86/90R, and D86/90G). Replacing the
catalytic cysteine residue 61 by an alanine in BPLF1C61A has
been shown to abolish enzymatic activity [31]. Besides acting as a
DUB, BPLF1 is capable of hydrolyzing Nedd8 conjugates and
affects the major cellular neddylated proteins, the cullins [38,39].
Two mutants, BPLF1D86/90R and BPLF1D86/90G, contain altered
charged residues at the protein surface that almost completely
prevent interaction with the cullin proteins and, therefore, no
longer deneddylate them. While the catalytic site C61 residue is
unaltered, enzymatic activities of these two mutants are differen-
tially affected, probably due to conformational changes in the
protein [39].
Transient transfection of these BPLF1 variants in 293T cells
resulted in similar protein expression levels (Fig. 3a, FACS; Fig. 3b,
immunoblot). In agreement with earlier reports, DUB labeling
with the fluorescent Ub-VME probe was abrogated by the C61A
catalytic site mutation, whereas BPLF1D86/90R and BPLF1D86/90G
maintained reactivity (Fig. 3b middle and lower panel, in gel-
fluorescence and subsequent immunoblot, respectively). The im-
munoblot depicted in figure 3b (lower panel) clearly shows the
larger and smaller BPLF1 fragments (lane 3) and their 10 kDa shift
upon covalent attachment of the active site probe (lanes 2, 4, and
5). Differences among the BPLF1 variants became more apparent
in a cellular assay for DUB activity, in which ubiquitinated
proteins in 293T cells were visualized through transfection with
HA-tagged ubiquitin (Fig. 3c). In this assay, potent deubiquitina-
tion was mediated by wild-type (wt) BPLF1 (lane 3) and, to a
slightly lesser extent, by BPLF1D86/90G (lane 6); BPLF1D86/90R
had largely lost its capacity to remove HA-ubiquitin from cellular
proteins (lane 5), as did the catalytic mutant BPLF1C61A (lane 4).
We next examined the effects of expressing wt BPLF1 or the
three mutants on TLR signaling. To this end, 293T cells were
transfected to transiently (co-)express the TLR2 protein (Fig. 3d).
NF-kB activation following MALP-2 treatment of these cells was
inhibited by wt BPLF1 and, to a lesser extent, by BPLF1D86/90G.
In contrast, both the catalytically inactive mutant BPLF1C61A as
well as BPLF1D86/90R did not reduce NF-kB activation. As TLR
interference by these BPLF1 variants (Fig. 3d) correlates with their
reactivity towards intracellular Ub-protein adducts (Fig. 3c), we
conclude that the ability of BPLF1 to downmodulate TLR
signaling depends on its intracellular DUB activity.
BPLF1 acts at multiple levels in the TLR signal
transduction cascade
Regulation of TLR responses involves K48- and K63-linked
ubiquitination of various signaling intermediates. To delineate
where EBV BPLF1 acts to inhibit TLR signaling, we performed
the following experiments.
Transcription of type I IFNs and proinflammatory cytokines is
induced by NF-kB after its translocation into the nucleus upon
release from the cytosolic inhibitor IkBa. Downstream of TLR
stimulation, IkBa is targeted for proteasomal degradation by K48-
linked ubiquitination. To investigate whether BPLF1 interferes
with this process, we assessed IkBa levels in 293-TLR2/CD14
cells (Fig. 4a). In response to the TLR2 ligand MALP-2, IkBa
degradation became apparent in TLR2-expressing cells after
30 minutes of stimulation and this was counteracted by the cellular
DUB A20. Cellular expression of the EBV DUB BPLF1 likewise
prohibited IkBa degradation, whereas the catalytically inactive
mutant BPLF1C61A did not. Thus, BPLF1 interferes with TLR-
mediated NF-kB signaling at, or upstream of, the level of IkBa
degradation in a manner dependent on its DUB activity.
Several signaling intermediates upstream of IkBa are regulated
through K63-linked ubiquitination (Fig. 4b). To dissect these steps,
we stimulated the TLR signaling pathway at different levels by
transfection of 293T cells with the activator proteins MyD88,
IRAK1, TRAF6, or IKKa, and monitored ensuing NF-kB
activation in luciferase assays (Fig. 4c). Feasibility of this approach
is illustrated by two controls. Firstly, IkBa blocks NF-kB activation
downstream of IKKa, and IkBa expression therefore inhibited
responses induced by MyD88 down to IKKa. Secondly, A20 is
known to deubiquitinate TRAF6; A20 expression inhibited NF-kB
activation mediated by MyD88-, IRAK1-, and TRAF6, but not
IKKa. EBV BPLF1 reduced signaling induced by expression of all
four signaling intermediates. This inhibitory effect occurred
through deubiquitination, since the catalytic mutant BPLF1C61A
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did not alter NF-kB activation (Fig. 4c). These data point to
the EBV DUB targeting ubiquitinated signaling molecules at or
upstream of the IKKa/IKKb/NEMO complex.
Confocal microscopy was employed to study cellular colocaliza-
tion of the EBV-encoded DUB and three ubiquitinated interme-
diates in the TLR signaling pathway, a prerequisite for their direct
deubiquitination by BPLF1. 293T cells transfected with BPLF1
and either TRAF6, NEMO, or IkBa were fixed and permeabilized
and both EBV and signaling proteins were visualized with
specific antibodies. Colocalization in the cytoplasm was observed
for BPLF1 with TRAF6 and with NEMO (Fig. 5a). Transfec-
tion of IkBa results in nuclear localization of this signaling
intermediate [43] and, therefore, colocalization with BPLF1 was
detected in the nucleus (Fig. 5a). We next determined whether
cytoplasmic colocalization with BPLF1 affected K63-linked
polyubiquitination of TRAF6 or NEMO, by comparing cells
Figure 2. BPLF1 interferes with TLR-mediated NF-kB activation. 293T cells were transiently transfected with a firefly luciferase reporter
construct responsive to either NF-kB activation or IFNb promoter activity, an HSV TK-promoter driven Renilla luciferase plasmid (for normalization),
and plasmids encoding HA-BPLF1, Flag-BXLF1, Flag-BSLF1 or cellular control DUB A20. (a) An NF-kB responsive firefly luciferase reporter and 4 or
8 ng of vectors encoding the EBV or control proteins were cotransfected in 293T cells and the TLR signaling cascade was initiated by expressing
adaptor protein MyD88. Sixteen hours post-transfection, cells were lysed and luciferase activity was determined. In addition, protein expression was
analyzed in post-nuclear cell lysates by immunoblot using anti-HA and anti-Flag Abs; b-actin served as loading control. (b) 293-TLR2/CD14 cells were
cotransfected with an NF-kB responsive reporter and 32 ng of plasmids encoding the indicated proteins. Starting at 16 hours post-transfection, cells
were stimulated with 10 ng/mL MALP-2 or 6.56106 EBV particles/mL for 7 hours, after which they were lysed and luciferase activity was measured. (c)
Similarly, 293-TLR3 cells were cotransfected with 16 ng of the indicated genes together with an NF-kB responsive reporter (left panel) or a reporter
under control of the IFNb promoter (right panel). Starting 16 hours post-transfection, cells were stimulated for 7 hours with 10 mg/mL poly(I:C), after
which they were lysed and luciferase activity was determined. Data are presented as percentages firefly luciferase activity relative to stimulated
control samples and normalized for transfection efficiency using Renilla luciferase values, mean 6 SD. (d) 293-TLR2/CD14 cells were transfected with
empty control vector or plasmids encoding EBV BPLF1 or cellular A20. Starting at 24 hours post-transfection, cells were stimulated with 10 mg/mL
MALP2 or 6.56106 EBV particles/mL for 8 hours. IL-8 secretion in the culture supernatants was determined by ELISA.
doi:10.1371/journal.ppat.1003960.g002
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expressing TRAF6 or NEMO in the absence or presence of
DUBs. Immunoprecipitation from post-nuclear lysates of 293T
cells co-expressing HA-ubiquitin revealed a smear of polyubi-
quitinated TRAF6 (Fig. 5b, upper panel lane 1) and polyubiqui-
tinated NEMO (Fig. 5b, lower panel lane 1). Co-expression of wt
BPLF1 in these cells caused a marked reduction in the amounts
of ubiquitinated TRAF6 and NEMO (lanes 2), which was not
induced by the catalytically inactive DUB mutant BPLF1C61A
(lanes 3). As a positive control, A20 also reduced poly-ubiquitination
of TRAF6 (upper panel lane 4), but not of NEMO (lower panel lane
4). These data strongly indicate that cytoplasmic BPLF1 can remove
K63-linked ubiquitin moieties from TRAF6 and NEMO.
Finally, to directly assess if BPLF1 can enzymatically act on
both K63-linkages as well as K48-linkages present on ubiquiti-
nated TRAF6 and NEMO, versus IkBa, we compared the in vitro
deubiquitinase activity of isolated (in)active DUBs towards these
Figure 3. BPLF1-mediated modulation of TLR signaling correlates with deubiquitinase activity. 293T cells were transiently transfected
with an empty vector control or plasmids encoding Flag-tagged BPLF1 or mutants thereof (BPLF1C61A, BPLF1R86/R90, or BPLF1G86/G90). (a) Sixteen
hours post-transfection, the percentage of cells expressing BPLF1 was determined by intracellular flow cytometric analysis using an anti-Flag Ab. (b,
upper panel) Post-nuclear cell lysates were prepared and immunoblotted using an anti-Flag Ab. The asterisk marks a smaller active fragment
observed upon expression of BPLF1. (b, middle panel) Active DUBs in these cell lysates were labeled using the fluorescent Ub-VME probe (causing a
concomitant size increase of 10 kDa) and visualized by in-gel imaging. (b, lower panel) Immunoblot of the gel in c probed with BPLF1-specific Ab
2E5. Unlabeled BPLF1 migrates at 36 kDa and 32 kDa, while the upper two bands of 46 kDa and 42 kDa represent probe-bound BPLF1. (c) 293T cells
were cotransfected with HA-ubiquitin and BPLF1 variants. After 40 hours, total lysates were prepared and immunoblotted for HA-Ub-protein adducts
using an anti-HA Ab (left panel; right panel shows the quantification of average staining intensities from four independent experiments). Expression
levels of BPLF1 variants were assessed using an anti-Flag Ab; b-actin served as loading control. (d) 293T cells were cotransfected with vectors
encoding TLR2, an NF-kB responsive firefly luciferase reporter, HSV TK-driven Renilla luciferase for normalization, and BPLF1 variants (16 ng).
Following treatment with 10 ng/mL MALP-2 for 7 hours, cells were lysed and luciferase activity was measured. The data are presented as percentage
firefly luciferase activity relative to stimulated control sample and normalized for transfection efficiency using Renilla luciferase values, mean 6 SD.
doi:10.1371/journal.ppat.1003960.g003
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targets (Fig. 5c). In line with the results observed upon their
cellular coexpression (Fig. 5b), in vitro incubation of ubiquitinated
TRAF6 or NEMO with wt BPLF1 resulted in removal of
polyubiquitin chains, which did not occur upon incubation with
the inactive mutant BPLF1 C61A (Fig. 5c, left and middle panels).
The cellular DUB A20 only affected ubiquitination of TRAF6, but
not of NEMO. Since K48-linked (as opposed to K63-linked)
polyubiquitination results in proteasomal degradation, IkBa
transfected cells were additionally stimulated with TNFa and
treated with a proteasome inhibitor to obtain sufficient amounts of
ubiquitinated signaling protein for evaluation in an in vitro DUB
assay. Polyubiquitinated IkBa was also targeted by BPLF1, but not
by the inactive mutant or A20 (Fig. 5c right panel), showing
that the EBV DUB can interfere with K48-ubiquitin-regulated
proteasomal degradation of IkBa.
Taken together, our results indicate that BPLF1 inhibits NF-kB
activation by targeting multiple K48- and K63-ubiquitin-regulated
steps along the TLR signaling pathway.
BPLF1 is expressed during the late phase of productive
EBV infection and is incorporated into viral particles
Conflicting information has been published on the timing of
expression of the EBV DUB during productive infection, with
BPLF1 being classified either as a late viral gene based on
promoter consensus sequences [44], or as an early gene based on
the kinetics of mRNA expression [38]. Our new BPLF1-specific
monoclonal Ab provides the opportunity to address this issue by
determining natural BPLF1 expression kinetics at the protein level.
We examined expression of EBV proteins in post-nuclear lysates
of AKBM cells at various times after induction of the lytic cycle
(Fig. 6a and b). The immediate early viral protein BZLF1 was
readily detected at 4 hours post induction and onwards, followed
by the early BGLF5 protein, and the late structural glycoprotein
gp42 at 8–12 hours post induction. The BPLF1 protein appeared
in productively infected AKBM cells after 8–12 hours, coincident
with the timing of gp42 expression (Fig. 6b). To confirm the late
kinetics of BPLF1 expression, phosphonoacetic acid (PAA) was
Figure 4. BPLF1 interferes with TLR signal transduction at multiple levels. (a) 293-TLR2/CD14 cells and control 293-CD14 cells were
transiently transfected with plasmids encoding Flag-tagged BPLF1, catalytically inactive mutant BPLF1C61A, or cellular control DUB A20. At 40 hours
post-transfection, cells were treated with 10 ng/mL MALP-2 for indicated time periods and IkBa levels in post-nuclear cell extracts were determined
by immunoblotting with an anti-IkBa Ab. Expression of transfected Flag-tagged proteins was assessed by immunoblotting with an anti-Flag Ab; TfR
served as loading control. (b) Schematic representation of the signaling cascade that induces NF-kB following TLR activation. Ub in green is K63-
linked, Ub in purple is K48-linked. (c) 293T cells were cotransfected with an NF-kB responsive firefly luciferase reporter, HSV TK promoter-driven
Renilla luciferase for normalization, and plasmids expressing BPLF1, BPLFC61A, or controls IkBa and A20 (13.5 ng). TLR signaling was induced by
expression of activator proteins MyD88, IRAK1, TRAF6, or IKKa. After 16 hours of transfection, luciferase activity was measured. Results are depicted as
percentage firefly luciferase activity normalized using Renilla luciferase values relative to stimulated control sample, mean 6 SD.
doi:10.1371/journal.ppat.1003960.g004
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Figure 5. EBV DUB BPLF1 can target K63- and K48-ubiquitinated signaling intermediates. (a) Fluorescence micrographs of 293T cells that
were cotransfected with plasmids encoding Flag-TRAF6 and HA-BPLF1 (upper panel), NEMO and Flag-BPLF1 (middle panel), or IkBa and Flag-BPLF1
(lower panel). Sixteen hours post-transfection, signaling intermediates (column 2) and BPLF1 (column 3) were labeled using anti-Flag (red; for TRAF6
in upper panel; for BPLF1 in middle and lower panels), anti-BPLF1 (green), anti-NEMO (green), and anti-IkBa (green) Abs as indicated. Nuclei were
visualized using TO-PRO-3 (blue, column 1). Column 4 and 5 show merged pictures from red and green channels without and with nuclear stain
(blue), respectively. Scale bar 50 mm. (b) 293T cells were cotransfected with plasmids encoding either Flag-TRAF6 (upper panel) or His-NEMO (lower
panel) together with HA-ubiquitin and BPLF1, BPLF1C61A, or A20. Expression of Flag-tagged proteins was assessed by immunoblotting (IB) with an
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added during anti-IgG treatment of EBV+ AKBM cells and the
EBV2 AK31 control cells (Fig. 6c). PAA is an inhibitor of viral DNA
replication and prevents late gene expression in productively infected
B cells [45]. While BZLF1 and BGLF5 proteins were expressed in
lytic AKBM cells irrespective of PAA treatment (lanes 6 and 7), the
inhibitor blocked synthesis of both BPLF1 and the control late EBV
protein gp42 (lane 7). Finally, we analyzed purified EBV particles
(strain B95.8): in addition to the envelope protein gp42, we also
found the full-length BPLF1 protein to be present (Fig. 6c, lane 1).
Taken together, these results show that the EBV DUB BPLF1 is
expressed during the late phase of productive infection and is
incorporated into viral particles, providing various opportunities
for interference with TLR signaling.
Discussion
In this study, we have shown that the large tegument protein
BPLF1 acts as an active DUB during productive EBV infection.
By removal of K63- and/or K48-linked ubiquitin chains from
signaling intermediates, such as TRAF6, NEMO, and/or IkBa,
BPLF1 inhibits TLR signaling through both MyD88- and TRIF-
dependent pathways. This leads to reduced NF-kB activation and
proinflammatory cytokine production in response to EBV.
The first herpesvirus-encoded DUB was identified by covalent
binding of a ubiquitin-based active site-directed probe to the large
tegument protein expressed in HSV1-infected cells [30]. The
catalytic site of this DUB appeared to be conserved in the large
anti-Flag Ab. TRAF6 and NEMO were precipitated (IP) from post-nuclear lysates and detected using an anti-TRAF6 or anti-His Ab, respectively. HA-
tagged ubiquitin adducts were visualized on immunoblot using anti-HA Abs. (c) 293T cells were cotransfected with plasmids encoding HA-ubiquitin
together with Flag-TRAF6 (left panel), His-NEMO (middle panel), or IkBa (right panel). IkBa-transfected cells were additionally treated with TNFa and
the proteasome inhibitor MG132 for 2 hours before lysis. Twenty-four hours post-transfection, TRAF6, NEMO, and IkBa were precipitated from post-
nuclear cell lysates and incubated in vitro with separately purified Flag-BPLF1, Flag-BPLF1C61A, or Flag-A20 proteins for 4 hours at 37uC. Flag-tagged
DUBs were detected by immunoblotting with anti-Flag Ab and signaling intermediates were visualized using anti-Flag (TRAF6), anti-His (NEMO), or
anti-IkBa Abs. HA-ubiquitin adducts were detected using an anti-HA Ab.
doi:10.1371/journal.ppat.1003960.g005
Figure 6. BPLF1 is expressed during the late phase of lytic EBV infection and is incorporated into viral particles. EBV+ AKBM cells were
treated with anti-human IgG (aIgG) to induce productive infection. (a) At the indicated times post-induction, percentages of AKBM cells undergoing
productive infection were determined by flow cytometric analysis of ratCD2-GFP reporter expression. (b) EBV protein expression in post-nuclear cell
lysates was determined by immunoblotting with Abs specific for BZLF1 (immediate early, IE), BGLF5 (early, E), and gp42 (late, L). b-actin served as
loading control. (c) Immunoblot of post-nuclear lysates of EBV B95.8 particles (lane 1), EBV2 AK31 cells (lanes 2–4), and EBV+ AKBM cells (lanes 5–7).
EBV+ AKBM cells and EBV2 control AK31 cells were treated with aIgG Abs for 24 hours, resulting in productive infection in 26% of AKBM cells; AK31
cells expressed ratCD2-GFP constitutively in ,40% of the population (data not shown). Phosphonoacetic acid (PAA, 300 mg/mL) treatment starting
1 hour prior to anti-IgG treatment was used to inhibit late protein expression; b-actin served as loading control.
doi:10.1371/journal.ppat.1003960.g006
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tegument protein of all herpesviruses [31]. Based on the structure
of the MCMV homologue, M48, the herpesvirus DUBs form a
unique class of cysteine proteases that do not share homology with
cellular deubiquitinating enzymes, except for the catalytic site triad
[30,46]. Both in vitro and in vivo studies support important roles for
the conserved tegument DUBs during the viral life cycle. For
example, an HCMV UL48 mutant virus yielded reduced viral
titers in cultured cells [47]. A mutant of HSV, from which the
homologous tegument gene UL36 had been completely deleted,
did not assemble virions (late in infection) and failed to enter the
nucleus (at early stages of infection) [48]. MHV-68 expressing a
catalytically inactive DUB encoded by ORF64 had reduced in vitro
replication capacity and was cleared more efficiently in vivo [49].
For EBV, knockout or knockdown of BPLF1 expression in
lytically infected 293T or B cells, respectively, resulted in reduced
virus production [38,40,50]. So far, one viral substrate of BPLF1
has been found: deubiquitination of the subunit BaRF1 reduced
activity of the EBV ribonucleotide reductase complex [40].
Among the reported cellular targets of BPLF1 is PCNA [41],
deubiquitination of which prevents recruitment of DNA damage
response elements. The cullins form cellular substrates for
deneddylation by BPLF1. As a consequence of active BPLF1
expression, the cullin-RING ligase neddylation cycle is interrupted
leading to an S-phase cell cycle arrest that favors EBV replication
[38,39].
Although the N-terminal fragment of the homologous large
tegument protein of EBV has been reported to exert DUB activity
[31,38,40,51], earlier attempts were unsuccessful in finding the
active BPLF1 protein in EBV-infected B cells [52]. Combining our
EBV lytic cycle system with a sensitive fluorescently labeled Ub-
VME probe and new BPLF1-specific monoclonal Abs has now
revealed an active DUB protein corresponding to full-length
BPLF1 in EBV-producing B cells (Fig. 1). This complements the
finding by Whitehurst et al. [41] of endogenous BPLF1 expression
in lytically induced 293T-BAC EBV cells. While our manuscript
was under revision, Gastaldello et al. [42] reported detection of
BPLF1 as an active deneddylase as well as DUB in a related cell
line, Akata-BX1, thereby confirming the reproducibility of our
findings. BPLF1 is expressed as a late lytic cycle gene product and
is incorporated into viral particles (Fig. 6). BPLF1’s presence in
virions is also supported by detection of this high molecular weight
protein (indicated as large tegument protein, LTP) among EBVs
structural proteins [53]. Two other reported putative EBV DUBs,
BXLF1 and BSLF1, were not detectable as active DUBs in EBV-
producing B cells or in transfected cells (Fig. 1). Cellular expression
of full-length as well as a 325 aa N-terminal domain of BPLF1
yielded an additional smaller fragment, as also observed by others
[38,42]. Based on its size this fragment corresponds to residues 1-
,280 of BPLF1, including the active site cysteine, and was shown
to exert DUB activity (Figs. 1, 3, 5). Our preliminary data indicate
that full-length BPLF1 disappeared in time (at ,48 hours in lytic
AKBM cells, Fig. S3c; from ,72 hours in 293T cell transfected
with FL BPLF1, most clearly visible as loss from the cytosol of the
C-terminal HA-tag, Fig. S3b) and a smaller fragment appeared
(reactive with the DUB probe and Abs specific for epitopes
spanning BPLF1 aa 2–17 (peptide A) and 78–94 (peptide B); Figs.
S2 and S3). This likely occurs due to processing of the full-length
protein, as it coincided with appearance of N-terminal fragments
of BPLF1 migrating around 32 and 25 kDa (detectable with anti-
BPLF1 peptide A Ab, Fig. S3b; and with anti-Flag Ab, not shown).
Shorter fragments of BPLF1 of #32 kDa would lack nuclear
localization sequences (aa 412–418) and might localize preferably
to the cytoplasm. The ,32 kDa fragment was indeed observed in
cytoplasmic (and nuclear) fractions, yet the ,25 kDa form was
restricted to the nucleus (Fig. S3b). This is in accordance with a
very recent publication, where a nuclear ,25 kDa fragment of
BPLF1 was found to result from cleavage of the viral protein by
caspase 1; the resulting small molecular size (#40 kDa) could
allow diffusion through the nuclear pore, which would thus
facilitate deNeddylase activity towards the Cullin substrates in the
nucleus [42]. We here propose that the ,32 kDa fragment could
exert DUB activity towards substrates that reside in the cytoplasm.
Intracellular processing could thus regulate BPLF1’s (subcellular)
localization and activity. This is reminiscent of the dual role of
UL36 in HSV1 infection: at late times, full-length UL36 functions
as a structural/tegument protein in virion assembly from virus-
producing cells, whereas at early times the protein is cleaved upon
entry into newly infected cells in order to allow nuclear release of
the viral DNA [54–56]. Since full-length and/or truncated large
tegument proteins with DUB activity have additionally been
reported for HCMV [57] and MHV68 [29], this may represent a
general feature among these conserved viral DUBs.
In the current study, we have found that BPLF1 interferes with
innate immune activation by targeting multiple intermediates
along the TLR signal transduction pathway, including TRAF6,
NEMO, and IkBa (Figs. 2, 4, and 5). Interestingly, Saito et al. very
recently also reported TRAF6 to be deubiquitinated by BPLF1
[50], albeit in a different context. They reported that BPLF1
contributed to virus production by repressing NF-kB signaling,
which is induced in latently infected EBV+ cells by the EBV latent
membrane protein 1 (LMP1) and signaled through TRAF6 [50].
Although in our system, BPLF1 is not detectable in latently EBV-
infected B cells, simultaneous expression of BPLF1 and LMP1
could occur in B cells during productive infection. In agreement
with published results [58], low levels of LMP1 were expressed
from 8 hours of lytic induction of AKBM B cells and higher levels
of the shorter, lytic form of LMP1 (lyLMP1) were detected in cell
lysates of 24 and 48 hours post-induction (Fig. S4). LyLMP1 does
not activate NF-kB signaling itself and in fact appears to
counteract (latent FL) LMP1 signaling [59,60]. Whereas during
latency LMP1 provides proliferative and survival signals through
NF-kB, lyLMP1 could cooperate with BPLF1 to reduce NF-kB
activation in B cells producing new virions. In our study, we
addressed another implication of BPLF1’s DUB function for virus-
host interactions. BPLF1 inhibited NF-kB activation and proin-
flammatory cytokine production in response to TLR stimulation,
e.g. by EBV particles (Fig. 2). In addition, we have identified likely
targets downstream of TRAF6 that are relevant to this TLR
inhibition: BPLF1 colocalizes with and can deubiquitinate K63-
Ub-TRAF6, K63-Ub-NEMO, and K48-Ub-IkBa (Figs. 4 and 5).
The mechanistic experiments were mostly performed in 293T cells
with BPLF1 expressed in isolation, yet the expression levels of the
signaling components we studied appeared comparable in the B
cells used for productive EBV infection (data not shown).
Employing mutants of BPLF1 (D86/90) that retained an unaltered
catalytic site, but no longer interact with the cullins [39], we
observed that inhibition of NF-kB activation correlated with DUB
activity of the mutants (Fig. 3). From this, we deduced that the
TLR evasive properties of BPLF1 rely on its deubiquitinase, rather
than its deneddylase, activity. This places EBV BPLF1 in the
arena of viral proteins that target protein ubiquitination.
As ubiquitination represents a post-translational modification
that plays a regulatory role in NF-kB- and IRF-mediated
immunity through protein degradation and signal transduction,
it comes as no surprise that viruses have found ways to interfere
with the process. On the one hand, ubiquitin conjugation can be
altered in virus-infected cells. Examples include poxvirus-induced
inhibition of ubiquitin-dependent degradation of IkBa via
EBV Deubiquitinase Inhibits TLR Signaling
PLOS Pathogens | www.plospathogens.org 13 February 2014 | Volume 10 | Issue 2 | e1003960
sequestration of the cellular E3 ligase involved [61] and KSHV
Rta-encoded E3-ligase activity that invokes degradation of IRF7
[62]. On the other hand, increased deubiquitination imposed by
viruses can also shift the balance. For instance, the cellular DUB
UCHL1 appears to be upregulated by HPV16 infection leading to
suppressed innate signaling through TRAF3 and NEMO [63].
The HSV tegument protein ICP0 [64] recruits the cellular DUB
USP7 into the cytosol to switch off TLR signaling to NF-kB. More
recently, virus-encoded DUBs were found to dampen innate
responses towards both RNA viruses [65,66] and DNA viruses,
adenovirus [67] and KSHV [68]. Here we demonstrate that EBV
BPLF1 also exploits its DUB activity to modulate TLR signaling.
Herpesviruses are ancient viruses and have evolved in close
association with their hosts, leading to acquisition of extensive
strategies to perturb host immunity. A common strategy emerged
from studies on viral evasion of host adaptive immune mecha-
nisms. This is exemplified by EBV, where multiple viral proteins
target the HLA class I-restricted antigen presentation pathway to
ensure the optimal timing and extent of inhibition of host
immunity [69]. Viruses have adopted a similar strategy to achieve
innate immune evasion. Poxviruses have already been found to
encode a number of inhibitors for the NF-kB pathway [70].
During productive EBV infection, the past years have also
witnessed identification of a number of TLR evasion strategies.
The viral tegument protein LF2 prevents activation of IRF7 [71]
and the immediate-early transactivator BZLF1 negatively regu-
lates IRF7-induced responses [72]. Of the early EBV early
proteins, the viral kinase BGLF4 inhibits IRF3 activation [73] and
the shutoff protein BGLF5 reduces TLR expression levels [23].
Here, we have reported on the large tegument protein BPLF1,
expressed at late times of infection, downregulating TLR signaling
through its DUB activity. Since tegument proteins such as BPLF1
are packaged into viral particles, they are transferred directly into
newly infected cells (Fig. 7). Its close association with the EBV
capsid would suggest that BPLF1 is present when PAMPs are
activating innate receptors and cleavage of the N-terminal domain
of BPLF1 might then allow deubiquitination to take place. It is
tempting to speculate that deubiquitination by this EBV protein
may exert its immunomodulatory functions in particular during
primary infection. If and how this occurs awaits future elucidation.
Figure 7. Schematic model of BPLF1-mediated TLR evasion during EBV infection. During EBV infection, EBV components are sensed by
host TLRs (a). These receptors activate signaling pathways through adaptor molecules MyD88 and TRIF, culminating in activation of transcription
factor NF-kB (b). NF-kB induces production of proinflammatory cytokines (c) and obstructs viral replication. TLR signaling pathways are extensively
regulated by ubiquitination, a process governed by cellular ubiquitin ligases and deubiquitinases (e.g. A20, d). The EBV-encoded DUB BPLF1
counteracts TLR-mediated NF-kB activation and can interfere with K63- and K48-linked ubiquitination of signaling intermediates, for example on
TRAF6, NEMO, and IkBa (e). BPLF1 is expressed as a full-length protein during the late phase of productive EBV infection, is incorporated into the
tegument of viral particles (f), and can subsequently be released into newly infected cells (g). It is as yet unclear where BPLF1 is processed to yield a
shorter active fragment of ca. 280 aa (see Fig. 1). Thus, (processed) BPLF1 could exert its immunomodulatory functions towards TLR signaling not only
in EBV-producing B cells (h), but also during primary infection (g).
doi:10.1371/journal.ppat.1003960.g007
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Supporting Information
Figure S1 Enlarged view of the upper part of the gel
depicted in Fig. 1b. For details, see legend Fig. 1b.
(TIF)
Figure S2 BPLF1-specific monoclonal antibodies. Rat
monoclonal Abs were generated against peptides encompassing
residues 2–17 (peptide A) and residues 78–94 (peptide B) of EBV
strain B95.8-encoded BPLF1. (a) Sequence alignment of the N-
terminal parts of BPLF1 (aa 1–325) derived from the EBV strains
B95.8 and Akata. An asterisk indicates the amino acid difference
between these strains at position 12 (T12P). (b) Reactivity of two
BPLF1-specific (IgG2a) mAbs 2E5 and 1F2 was tested in
immunoblot. 293T cells were transiently transfected with plasmids
encoding the N-terminal domains of BPLF1 from EBV strains
B95.8 and Akata; transfection efficiencies were comparable
(,60% positive cells). Sixteen hours after transfection, post-
nuclear cell lysates were prepared, separated by SDS-PAGE, and
immunoblots were stained with an anti-Flag Ab or anti-BPLF1
Abs directed against peptide A (2E5) or peptide B (1F2). Equal
loading was demonstrated by comparable band intensity observed
upon staining for the Flag-tag (lanes 5 and 6); this was further
supported by the staining with Ab 1F2 that reacts with an epitope
identical in both EBV strains (lanes 3 and 4). The T12P amino
acid difference strongly reduced 2E5-mediated detection of Akata-
derived BPLF1 compared to B95.8-derived BPLF1 (lanes 1 and 2).
An asterisk indicates the smaller fragment arising upon cellular
expression of BPLF1. Since this 32 kDa band is recognized by
both the anti-Flag Ab (tag at N-terminus) as well as the two
BPLF1-reactive Abs (aa 2–17 and 78–94), it likely represents a
truncated N-terminus of BPLF1 (residues 1- ,280). (c) BPLF1-
specific monoclonal Abs were tested in immunoprecipitation
experiments. 293T cells were transfected with Flag-tagged N-
terminal domains of B95.8- and Akata derived BPLF1, or Flag-
BXLF1 as control. Immunoprecipitations were performed in post-
nuclear lysates using monoclonal anti-BPLF1 Abs 21E9 (peptide
B, lanes 2 and 4), 2E5 (peptide A, lane 3), and 1F2 (peptide A, lane
5), or anti-Flag Ab (lane 1) under native conditions or after
denaturing proteins by incubating with 1% SDS as indicated. Ab
21E9 appeared ineffective in precipitating BPLF1, while 2E5 and,
to a lesser extent, 1F2 precipitated B95.8 as well as Akata-derived
BPLF1 under native and denaturing conditions, respectively.
(TIF)
Figure S3 BPLF1 expression in time. (a) Schematic
representation of the EBV BPLF1 protein. Green boxes indicate
peptides used to generate BPLF1-specific rat monoclonal Abs
(2E5, anti-peptide A, aa 2–17; 1F2, anti-peptide B, aa 78–94).
Asterisks denote aa substitutions of the mutants used in this study.
NLS: nuclear localization signal. Numbers refer to aa positions in
EBV strain B95.8. (b) 293T cells were transfected with plasmids
encoding Flag-tagged BPLF1, HA-tagged BPLF1 or full length
BPLF1 containing an N-terminal Flag-tag and C-terminal HA-tag
(Flag-FL BPLF1-HA). At 24, 48, and 72 hours post-transfection,
cytosolic (C) and nuclear (N) fractions were prepared and analyzed
by immunoblotting with anti-BPLF1 (2E5) and anti-HA Abs.
Adequate separation of cytosolic and nuclear fractions was
evaluated by immunoblot analysis of cytosolic p97 and nuclear
histon H3 using specific Abs. Left and right panels are part of the
same gels presented at different exposures. The asterisk indicates
the ,32 kDa cytosolic fragment observed over time upon expres-
sion of FL BPLF1. (c) Immunoblot using BPLF1-specific Ab 1F2
shows BPLF1 expression and processing in EBV+ AKBM cells
(lanes 4–7) and transfected 293T cells (lanes 1–3). AKBM cells
were treated with anti-IgG Abs to induce productive infection and
post-nuclear lysates were prepared after the indicated time
periods. 293T cells were transfected with constructs encoding
the N-terminal domain of BPLF1 (aa 1–325), full-length BPLF1,
or an empty control plasmid (C). The asterisk indicates the smaller
BPLF1 fragment observed at 24 and 48 hours after induction of
productive EBV infection in AKBM cells (lanes 6 and 7) and upon
expression of full-length BPLF1 in transfected 293T cells (lane 3).
(TIF)
Figure S4 LMP1 expression during productive EBV
infection in AKBM cells. EBV+ AKBM cells were treated
with anti-human IgG (a´IgG) to induce productive infection. At the
indicated times post-induction, expression of LMP1 was deter-
mined in post-nuclear cell lysates by immunoblotting using a
specific Ab (lanes 2–6). LMP1 expression was observed starting
8 hours after induction of lytic infection. Lytic LMP1 (lyLMP1), an
inhibitory variant of LMP1 that counteracts LMP-1 mediated
activation of signaling pathways, is expressed at 24 hours post
infection. Samples were the same as used for Figure 6b. EBV+
latency III cell line Jijoye constitutively expressing LMP1 was
included as a positive control (lane 1).
(TIF)
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